Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Polyunsaturated Fatty Acids in Emerging Psychosis

Author(s): Nilufar Mossaheb, Monika Schloegelhofer, Miriam R. Schaefer, Paolo Fusar-Poli, Stefan Smesny, Pat McGorry, Gregor Berger and G. Paul Amminger

Volume 18, Issue 4, 2012

Page: [576 - 591] Pages: 16

DOI: 10.2174/138161212799316055

Price: $65

Abstract

The role of polyunsaturated fatty acids and their metabolites for the cause and treatment of psychotic disorders are widely discussed. The efficacy as an augmenting agent in chronic schizophrenia seems to be small or not present, however epidemiological data, as well as some recent controlled studies in emerging psychosis point towards possible preventive effects of long-chain polyunsaturated fatty acids in early and very early stages of psychotic disorders and some potential secondary or tertiary beneficial long-term effects in later, more chronic stages, in particular for metabolic or extra-pyramidal side effects. In this comprehensive review, we describe the physiology and metabolism of polyunsaturated fatty acids, phospholipases, epidemiological evidence and the effect of these fatty acids on the brain and neurodevelopment. Furthermore, we examine the available evidence in indicated prevention in emerging psychosis, monotherapy, add-on therapy and tolerability. The neuroprotective potential of n-3 LC-PUFAs for indicated prevention, i.e. delaying transition to psychosis in high-risk populations needs to be further explored.

Keywords: Polyunsaturated fatty acids, essential fatty acids, omega-3 fatty acids, prodrome, psychosis, metabolites, psychotic disorders, neurodevelopment, monotherapy, membrane fluidity


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy